Holen Sie sich die Stockscreener-App
49.15
1.15%
0.56
Handel nachbörslich:
49.15
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
10 Biotech Stocks Screaming a Buy - Insider Monkey
PTC Therapeutics (PTCT): Truist Securities Initiates Coverage with 'Buy' Rating | PTCT Stock News - GuruFocus
Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - MarketScreener
Truist Financial Initiates Coverage on PTC Therapeutics (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Gains Buy Rating with Promising Drug Pipeline | PTCT Stock News - GuruFocus
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com
When the Price of (PTCT) Talks, People Listen - news.stocktradersdaily.com
GAMMA Investing LLC Increases Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Pallas Capital Advisors LLC Purchases New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Harbor Capital Advisors Inc. Sells 11,891 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics’ SWOT analysis: biotech stock’s potential in rare disease market - Investing.com Nigeria
PTC Therapeutics’ SWOT analysis: biotech stock’s potential in rare disease market By Investing.com - Investing.com South Africa
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Lowered by Assenagon Asset Management S.A. - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - Eastern Progress
Cantor Fitzgerald Weighs in on PTCT FY2026 Earnings - MarketBeat
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key - openPR.com
Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com
uniQure Prepares for Historic Huntington's Disease Treatment Launch with Key Executive Hire - Stock Titan
Encephalopathy Pipeline 2025: Comprehensive Clinical Trials - openPR.com
PTC Therapeutics at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com UK
Transcript : PTC Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 09 - marketscreener.com
Friedreich's Ataxia Market Set to Witness Rare Disease Drug - openPR.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Lessened by Public Employees Retirement System of Ohio - MarketBeat
William Blair Issues Pessimistic Estimate for PTCT Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PTC Therapeutics, Inc. (PTCT) And Encourages Shareholders to Reach Out - ACCESS Newswire
William Blair Predicts Lower Earnings for PTC Therapeutics - Defense World
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - sharewise
Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy - MSN
Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 108,345 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight - Yahoo Finance
PTC Therapeutics: Strong Buy Rating Backed by Promising Sepiapterin Launch and Robust Financial Outlook - TipRanks
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 26,274 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Mackenzie Financial Corp Boosts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Ameriprise Financial Inc. Has $1.94 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Price Target Raised by RBC Capital | PTCT Stock News - GuruFocus
RBC Capital raises PTC Therapeutics stock price target to $60 By Investing.com - Investing.com India
RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating - marketscreener.com
Trend Tracker for (PTCT) - news.stocktradersdaily.com
PTC Therapeutics at William Blair Conference: Strategic Growth and Innovation - Investing.com Canada
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - Yahoo Finance
PTC Therapeutics : William Blair 45th Annual Growth Stock Conference Presentation - marketscreener.com
Deepening digitalization in drug discovery at PTC therapeutics - SelectScience
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
RBC Capital maintains outperform rating for PTC Therapeutics stock By Investing.com - Investing.com Nigeria
Citi maintains neutral rating on PTC Therapeutics stock - Investing.com
PTCT Benefits from FDA's Flexible Approach to Huntington's Disea - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):